CAS 144689-63-4 manufacturers and suppliers on PharmaCompass

CAS 144689-63-4

Chemistry, 2 End Use API, 34 Related Intermediates

Manufacturers/Suppliers

2 Suppliers

2 Suppliers

MARKET PLACE

1 APIs

1 APIs

Also known as: 144689-63-4, Benicar, Olmetec, Cs-866, Cs 866, Nsc-758924

Molecular Formula

C₂₉H₃₀N₆O₆

Molecular Weight

558.6 g/mol

InChI Key

UQGKUQLKSCSZGY-UHFFFAOYSA-N

FDA UNII

6M97XTV3HD

An ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to manage HYPERTENSION.

1 2D Structure

CAS 144689-63-4

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate

2.1.2 InChI

InChI=1S/C29H30N6O6/c1-5-8-23-30-25(29(3,4)38)24(27(36)39-16-22-17(2)40-28(37)41-22)35(23)15-18-11-13-19(14-12-18)20-9-6-7-10-21(20)26-31-33-34-32-26/h6-7,9-14,38H,5,8,15-16H2,1-4H3,(H,31,32,33,34)

2.1.3 InChI Key

UQGKUQLKSCSZGY-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCC5=C(OC(=O)O5)C)C(C)(C)O

2.2 Other Identifiers

2.2.1 UNII

6M97XTV3HD

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy-4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(tetrazol-5-yl)phenyl)phenyl)methylimidazol-5-carboxylate - T287346

2. Benicar

3. Cs 866

4. Cs-866

5. Cs866

6. Medoxomil, Olmesartan

7. Olmetec

8. Votum

2.3.2 Depositor-Supplied Synonyms

1. 144689-63-4

2. Benicar

3. Olmetec

4. Cs-866

5. Cs 866

6. Nsc-758924

7. 6m97xtv3hd

8. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate

9. 1h-imidazole-5-carboxylic Acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl Ester

10. Ncgc00095136-01

11. Benevas

12. Olsertain

13. Olvance

14. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-imidazole-5-carboxylate

15. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1h-tetrazol-5-yl)-[1,1'-biphenyl]4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-imidazole-5-carboxylate

16. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(2h-tetrazol-5-yl)biphenyl-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-imidazole-5-carboxylate

17. Benicar (tn)

18. Olmetec (tn)

19. Cs866

20. Sr-05000001987

21. Unii-6m97xtv3hd

22. Votume

23. Openvas

24. Cs-866dm

25. Cs-866rn

26. Olmesartanmedoxomil

27. Olmesartan-medoxomil

28. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(1h-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate

29. Olmesartan Medoxomil [usan:inn:ban]

30. Ks-1182

31. Olmesartan (medoxomil)

32. Spectrum_001944

33. Spectrum2_000506

34. Spectrum3_001676

35. Spectrum4_000740

36. Spectrum5_001556

37. Dsstox_cid_25924

38. Dsstox_rid_81226

39. Dsstox_gsid_45924

40. Schembl16403

41. Bspbio_003491

42. Gtpl591

43. Kbiogr_001040

44. Kbioss_002498

45. 1h-imidazole-5-carboxylic Acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1h-tetrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl) Methyl Ester

46. Mls006010109

47. Spectrum1505205

48. Spbio_000431

49. Olmesartan Medoxomil (benicar)

50. Chembl1200692

51. Dtxsid9045924

52. Chebi:31932

53. Kbio2_002490

54. Kbio2_005058

55. Kbio2_007626

56. Kbio3_002711

57. Hms1922l15

58. Hms2089k18

59. Hms2093k16

60. Hms3651e13

61. Hms3715n09

62. Hms3743o09

63. Olmesartan Medoxomil (jp17/usp)

64. Olmesartan Medoxomil [inn]

65. Olmesartan Medoxomil [jan]

66. Pharmakon1600-01505205

67. Olmesartan Medoxomil [usan]

68. Amy22222

69. Bcp05214

70. Zinc4149248

71. Olmesartan Medoxomil [vandf]

72. Tox21_111445

73. Bdbm50442892

74. Ccg-39596

75. Mfcd00944911

76. Nsc758924

77. Olmesartan Medoxomil [mart.]

78. S1604

79. Stl451024

80. Olmesartan Medoxomil [usp-rs]

81. Olmesartan Medoxomil [who-dd]

82. Akos015894907

83. Akos015914772

84. Ac-1601

85. Bcp9000555

86. Ccg-221184

87. Cs-0577

88. Nsc 758924

89. Olmesartan Medoxomil, >=98% (hplc)

90. Sb19327

91. Ncgc00095136-02

92. Ncgc00095136-03

93. Ncgc00095136-09

94. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(2h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-imidazole-5-carboxylate

95. Azor Component Olmesartan Medoxomil

96. Hy-17005

97. Olmesartan Medoxomil [orange Book]

98. Smr002203616

99. Olmesartan Medoxomil [ep Monograph]

100. Sbi-0206741.p001

101. Olmesartan Medoxomil [usp Monograph]

102. Cas-144689-63-4

103. Ft-0601603

104. O0510

105. Olmesartan Medoxomil Component Of Azor

106. Sw199650-2

107. D01204

108. Tribenzor Component Olmesartan Medoxomil

109. Ab01275443-01

110. Ab01275443_02

111. Ab01275443_03

112. Benicar Hct Component Olmesartan Medoxomil

113. 689o634

114. A808260

115. L001061

116. Olmesartan Medoxomil Component Of Tribenzor

117. J-501595

118. Olmesartan Medoxomil Component Of Benicar Hct

119. Sr-05000001987-1

120. Sr-05000001987-2

121. Brd-k78485176-001-02-9

122. Brd-k78485176-001-03-7

123. Q27888058

124. Z1550675457

125. Olmesartan Medoxomil, European Pharmacopoeia (ep) Reference Standard

126. Olmesartan Medoxomil, United States Pharmacopeia (usp) Reference Standard

127. Olmesartan Medoxomil For System Suitability, European Pharmacopoeia (ep) Reference Standard

128. Olmesartan Medoxomil, Pharmaceutical Secondary Standard; Certified Reference Material

129. (5-methyl-2-oxidanylidene-1,3-dioxol-4-yl)methyl 5-(2-oxidanylpropan-2-yl)-2-propyl-3-[[4-[2-(2h-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate

130. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-i Midazole-5-carboxylate

131. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-imidazole-5-carboxylate

132. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-[[2'-(1h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]-4-(2-hydroxypr

133. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxy-2-propanyl)-2-propyl-1-[[2'-(1h-tetrazol-5-yl)-4-biphenylyl]methyl]-1h-imidazole-5-carboxylate

134. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl}-1h-imidazole-5-carboxylate

135. (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl1-((2'-(2h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-imidazole-5-carboxylate

136. (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl]imidazole-5-carboxylate

137. (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylate

138. (5-methyl-2-oxo-1,3-dioxolen-4yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylate

139. (5-methyl-2-oxo-2h-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1h-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1h-imidazole-5-carboxylate

140. 1h-imidazole-5-carboxylic Acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3- Dioxol-4-yl)methyl Ester

141. 1h-imidazole-5-carboxylic Acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl Ester

142. 5-(1-hydroxy-1-methylethyl)-2-propyl-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-imidazole-4-carboxylic Acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl Ester

143. 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]-4-imidazolecarboxylic Acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl Ester

144. Olmesartan Medoxomil

145. 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-imidazole-5-carboxylic Acid-(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl Ester

2.4 Create Date

2005-06-24

3 Chemical and Physical Properties

Molecular Formula	C₂₉H₃₀N₆O₆
Molecular Weight	558.6 g/mol
XLogP3	3.8
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	10
Rotatable Bond Count	11
Exact Mass	558.22268270 g/mol
Monoisotopic Mass	558.22268270 g/mol
Topological Polar Surface Area	154 Å²
Heavy Atom Count	41
Formal Charge	0
Complexity	969
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Information

1 of 8
Drug Name	OLMESARTAN MEDOXOMIL
Active Ingredient	OLMESARTAN MEDOXOMIL
Company	ACCORD HLTHCARE (Application Number: A207662); ALEMBIC PHARMS LTD (Application Number: A203012); ALKEM LABS LTD (Application Number: A206763); AUROBINDO PHARMA LTD (Application Number: A204798); GLENMARK PHARMS LTD (Application Number: A203281); JUBILANT GENERICS (Application Number: A205482); LUPIN LTD (Application Number: A206631); MACLEODS PHARMS LTD (Application Number: A204814); MYLAN PHARMS INC (Application Number: A078276); TEVA PHARMS USA (Application Number: A091079); TORRENT PHARMS LTD (Application Number: A202375); ZYDUS PHARMS USA INC (Application Number: A205192)

2 of 8
Drug Name	AZOR
Active Ingredient	AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL
Company	DAIICHI SANKYO (Application Number: N022100)

3 of 8
Drug Name	BENICAR HCT
Active Ingredient	HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL
Company	DAIICHI SANKYO (Application Number: N021532)

4 of 8
Drug Name	TRIBENZOR
Active Ingredient	AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL
Company	DAIICHI SANKYO (Application Number: N200175)

5 of 8
Drug Name	BENICAR
Active Ingredient	OLMESARTAN MEDOXOMIL
Company	DAIICHI SANKYO (Application Number: N021286)

6 of 8
Drug Name	AMLODIPINE AND OLMESARTAN MEDOXOMIL
Active Ingredient	AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL
Company	AJANTA PHARMA LTD (Application Number: A207216); ALEMBIC PHARMS LTD (Application Number: A207073); ALKEM LABS LTD (Application Number: A209042); AUROBINDO PHARMA LTD (Application Number: A206906); GLENMARK PHARMS LTD (Application Number: A207807); JUBILANT GENERICS (Application Number: A207450); MACLEODS PHARMS LTD (Application Number: A206884); MICRO LABS (Application Number: A207435); TEVA PHARMS USA (Application Number: A091154); TORRENT PHARMS LTD (Application Number: A202933); ZYDUS PHARMS USA INC (Application Number: A207771)

7 of 8
Drug Name	OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
Active Ingredient	HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL
Company	ALEMBIC PHARMS LTD (Application Number: A204233); AUROBINDO PHARMA LTD (Application Number: A205391); MYLAN PHARMS INC (Application Number: A078827); PRINSTON INC (Application Number: A207804); TEVA PHARMS USA (Application Number: A200532); TORRENT PHARMS LTD (Application Number: A206515)

8 of 8
Drug Name	OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE
Active Ingredient	AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL
Company	PAR PHARM INC (Application Number: A206137); TEVA PHARMS USA (Application Number: A202491); TORRENT PHARMS LTD (Application Number: A203580)

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

Antihypertensive Agents

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)

Angiotensin II Type 1 Receptor Blockers

Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS. (See all compounds classified as Angiotensin II Type 1 Receptor Blockers.)

5.2 FDA Pharmacological Classification

5.2.1 Pharmacological Classes

Angiotensin 2 Receptor Blocker [EPC]; Angiotensin 2 Receptor Antagonists [MoA]

5.3 ATC Code

C09CA08

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355

C - Cardiovascular system

C09 - Agents acting on the renin-angiotensin system

C09C - Angiotensin ii receptor blockers (arbs), plain

C09CA - Angiotensin ii receptor blockers (arbs), plain

C09CA08 - Olmesartan medoxomil

List of Suppliers

Full Screen View

Reset Filter

Ask Us

Prajna Generics

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

India

Virtual Booth

Digital Content

Olmesartan Medoxomil

PDF Supplier PDF

URL Supplier Web Content

CAS Number

144689-63-4

Intermediate Name

(5-methyl-2-oxo-1,3-dioxol-4-yl)met...

About the Company

Prajna is an innovation driven pharmaceutical company. We dedicated to Research, Process development and ...

Prajna is an innovation driven pharmaceutical company. We dedicated to Research, Process development and Manufacturing APIs and Advanced Intermediates for Active Pharmaceutical Ingredients (APIs) for the global pharmaceutical companies. It provides value-added services in Contract Research, Custom Synthesis, and Specialties Scientific technology (Green Process, APIs Process Development, Polymorphism, Crystallisation and Purification) for Pharmaceutical and Life Sciences industry.

ASK
US

Upload
your Marketing & Sales content

Vasudha Pharma Chem Limited

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

India

Virtual Booth

Digital Content

Olmesartan Medoxomil

PDF Supplier PDF

URL Supplier Web Content

CAS Number

144690-92-6

Intermediate Name

5-Methoxy-2-oxo-1,3-dioxol-4-yl)met...

About the Company

VASUDHA PHARMA CHEM LIMITED was incorporated, as a public limited company under the Companies Act, 1956 i...

VASUDHA PHARMA CHEM LIMITED was incorporated, as a public limited company under the Companies Act, 1956 in 1994-95 at Hyderabad in the state of Telangana, India. The company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates for catering to the Global market. Initially, the focus was on the development of cost effective processes for several intermediates related to piperidone & piperidine derivatives. By 2003-04, the company gained world class expertise and became the largest manufacturer of piperidone & piperidine derivatives in the world.

ASK
US

Upload
your Marketing & Sales content